Tobramycin sulfate: a summary of worldwide experience from clinical trials.
Tobramycin sulfate, a new bactericidal aminoglycoside antibiotic, has been evaluated in 3,506 patients. Its in vitro activity is similar to that of other aminoglycoside antibiotics, except that it is more active against Pseudomonas aeruginosa. Clincal studies have shown that tobramycin sulfate is well tolerated and effective in the treatment of the infections listed below when they are caused by susceptible gram-negative organisms and by staphylococci: infections of the respiratory tract (including cystic fibrosis), central nervous system, skin, soft tissue, and bone (including burns); urinary tract and intraabdominal infections; and septicemia. The overall response was satisfactory in greater than 86% of the patients. Drug-related adverse effects were reported in 3.9% of the patients, and included reactions in the nervous system in 0.6% and in the kidney in 1.5%.
D000005:Abdomen; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D001847:Bone Diseases / Q000188:drug therapy; D002493:Central Nervous System Diseases / Q000188:drug therapy; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D004064:Digestive System / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008099:Liver / Q000187:drug effects; D012141:Respiratory Tract Infections / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D012874:Skin Diseases, Infectious / Q000188:drug therapy; D014031:Tobramycin / Q000009:adverse effects / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy; D000159:Vestibulocochlear Nerve / Q000187:drug effects
D000900:Anti-Bacterial Agents; D014031:Tobramycin